2015-2018 "Urocidin™ is licensed to Endo, which will be responsible for global sales and marketing. Bioniche has retained the manufacturing rights for this product until the first patent on the product expires (around 2018). Patent extensions of five years are available in major markets, and the Company continues to file new patent applications related to this technology."
"It is estimated that full commercial approval will be received in both Canada and the USA (i.e., FDA approval and TPP (Therapeutic Product Protectorate (Health Canada) approval) in calendar 2015."